Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Amgen (NQ: AMGN )

294.53 +4.63 (+1.60%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Amgen

< Previous 1 2
...
10 11 12 13 14 15 16 17 18
...
47 48 Next >
3 Biotech Stocks to Buy in the TradeSmith ‘Green Zone’
It's now time to take a look at these three biotech stocks to buy, as each one is currently within TradeSmith's "Green Zone." 
Via InvestorPlace
Looking Into Amgen's Recent Short Interest
Via Benzinga
CRSP Stock Alert: CRISPR Therapeutics Is Losing Its Medical Chief
The fate of Crispr and CRSP stock will be determined by the success of other drugs in the company's pipeline rather than Casgevy. 
Via InvestorPlace
Amgen Provides Exposure To Obesity Drug At A Reasonable Price, Says Bullish Analyst
Amgen, Inc. (NASDAQ: AMGN) shares have been in focus amid developments in the AI-powered healthcare space. 
Via Benzinga
In-Depth Examination Of 18 Analyst Recommendations For Amgen
Via Benzinga
Uber To Rally Over 13%? Here Are 10 Top Analyst Forecasts For Tuesday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. 
Via Benzinga
Is Amgen Stock a Buy Now?
Boring businesses can be successful, too. 
Via The Motley Fool
Market Whales and Their Recent Bets on AMGN Options
Via Benzinga
Insights Into Amgen's Performance Versus Peers In Biotechnology Sector
Via Benzinga
Healthcare Sector Stocks: Consistent Above-Average Growth And Income
The healthcare sector is full of many really good companies with consistent, long term, above-average growth rates and many that have good, consistent, long-term dividend records. 
Via Talk Markets
1 Biotech Stock That Could Be the Next Amgen
The emergence of genomic medicine as a viable modality could transform this midcap biotech into the next Amgen. 
Via The Motley Fool
Better Growth Stock: Viking Therapeutics or Iovance Biotherapeutics?
Both of these pharma stocks could be big winners. But one stock screens as a better buy from a risk standpoint. 
Via The Motley Fool
PVH To Rally Around 11%? Here Are 10 Top Analyst Forecasts For Tuesday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. 
Via Benzinga
P/E Ratio Insights for Amgen
Via Benzinga
Looking Into Amgen's Recent Short Interest
Via Benzinga
Analyst Ratings for Amgen
Via Benzinga
1 Spectacular Dividend Stock Every Investor Should Consider
This biotech pioneer has been an exceptional growth and income stock. 
Via The Motley Fool
Why NASDAQ:AMGN is a Top Pick for Dividend Investors.
Why AMGEN INC (NASDAQ:AMGN) qualifies as a good dividend investing stock. 
Via Chartmill
Investigating Amgen's Standing In Biotechnology Industry Compared To Competitors
Via Benzinga
P/E Ratio Insights for Amgen
Via Benzinga
Quest For Alzheimer's Cure: Big Biotech Breakthroughs, But The Race Is Just Beginning
Biotech companies are edging closer to finding the answers behind Alzheimer's disease. 
Via Investor's Business Daily
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Investigating Amgen's Standing In Biotechnology Industry Compared To Competitors
Via Benzinga
2 Top Biotech Stocks to Buy Right Now
Don't give up on these stocks too fast. 
Via The Motley Fool
20 Analysts Have This to Say About Amgen
Via Benzinga
Amgen's Rare Autoimmune Disease Candidate Shows Improvement In Disease Burden In Treating Sjögren's Syndrome
Amgen Inc (NASDAQ: AMGN) released new  
Via Benzinga
Stock Market Rally Back In Force As Treasury Yields Plunge; Arista, Palantir Among Winners: Weekly Review
Bulls are back in control as the major indexes confirmed the uptrend this week. 
Via Investor's Business Daily
Amgen Wins Big With FDA, Analyst Sees Soaring Potential
The FDA approval of Amgen, Inc’s (NASDAQ: AMGN) biosimilar version of Johnson & Johnson's (NYSE: JNJ) psoriasis treatment, Stelara, for multiple inflammatory diseases sent 
Via Benzinga
Exposures Product Safety
These Analysts Revise Their Forecasts On Amgen After Q3 Results
Amgen Inc (NASDAQ: AMGN) reported mixed third-quarter financial results. 
Via Benzinga
5 Dow stocks to track during the market correction
The Dow Jones Industrial Average is struggling in correction territory, but savvy investors keep an eye on resilient stocks like Microsoft, Amgen, and Walmart. 
Via MarketBeat
Topics ETFs Stocks
Exposures US Equities
< Previous 1 2
...
10 11 12 13 14 15 16 17 18
...
47 48 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.